Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 533,798	$ 501,693	$ 1,053,157	$ 987,723
Product
Disaggregation of Revenue [Line Items]
Revenue	517,660	486,670	1,023,185	954,439
Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim
Disaggregation of Revenue [Line Items]
Revenue	480,333	458,542	961,476	876,302
Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | United States
Disaggregation of Revenue [Line Items]
Revenue	169,838	169,411	320,653	324,474
Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | Europe
Disaggregation of Revenue [Line Items]
Revenue	161,230	166,704	318,062	315,576
Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | Latin America
Disaggregation of Revenue [Line Items]
Revenue	89,911	42,248	152,455	101,953
Marketed by Company | Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | Rest of world
Disaggregation of Revenue [Line Items]
Revenue	59,354	80,179	170,306	134,299
Marketed by Sanofi | Aldurazyme
Disaggregation of Revenue [Line Items]
Revenue	$ 37,327	$ 28,128	$ 61,709	$ 78,137